Literature DB >> 23529389

Assessment of the diagnostic performance of (18)F-FDG-PET/CT for detection and characterization of solid renal malignancies.

Zein Nakhoda1, Drew A Torigian, Babak Saboury, Frank Hofheinz, Abass Alavi.   

Abstract

To evaluate the sensitivity of the positron emission tomography (PET) portion of fluorine-18 fluorodeoxyglucose- PET-computerized tomography ((18)F-FDG-PET/CT) to detect solid malignant renal masses, and to assess for metabolic differences based on histopathological type. Nineteen subjects with 25 known solid malignant renal masses who underwent (18)F-FDG-PET/CT were retrospectively evaluated. Qualitative analysis of the PET portion only of (18)F-FDG-PET/CT examinations to assess visual detection of renal masses was initially performed in blinded fashion. Subsequently, measurements of standardized uptake value (SUV) and lesion-to-background ratios were performed for all masses and compared between histopathological types. Of 25 solid malignant renal masses, 18 were renal cell carcinoma (RCC), 3 were renal lymphoma, and 4 were metastases. Twenty-two of 25 were detectable, and all were correctly spatially localized. Fifteen of 22 detectable lesions were exophytic in configuration. The three non-detectable masses were non-exophytic RCC's with average diameter of 2.0cm. Fifteen of 18 of RCC were detectable, whereas all renal lymphomas and metastases were detectable. None of the metabolic parameters were statistically significant between RCC and renal lymphoma. However, all metabolic parameters were statistically significantly greater for renal metastases compared to RCC and renal lymphoma, and for clear cell RCC compared to papillary RCC. In conclusion, the PET portion of (18)F-FDG-PET/CT had a sensitivity of 88% for detection of solid malignant renal lesions in patients with known renal malignancy, and reveals differences in metabolic activity based on histopathological type, which may be useful for purposes of individualized medicine. Further studies are required for more in depth assessment of these preliminary observations.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23529389     DOI: 10.1967/s002449910067

Source DB:  PubMed          Journal:  Hell J Nucl Med        ISSN: 1790-5427            Impact factor:   1.102


  9 in total

Review 1.  PET imaging in renal cancer.

Authors:  Liza Lindenberg; Esther Mena; Peter L Choyke; Kirsten Bouchelouche
Journal:  Curr Opin Oncol       Date:  2019-05       Impact factor: 3.645

Review 2.  Role of Positron Emission Tomography Imaging in Metabolically Active Renal Cell Carcinoma.

Authors:  Vidhya Karivedu; Amit L Jain; Thomas J Eluvathingal; Abhinav Sidana
Journal:  Curr Urol Rep       Date:  2019-08-29       Impact factor: 3.092

3.  Renal Masses Detected on FDG PET/CT in Patients With Lymphoma: Imaging Features Differentiating Primary Renal Cell Carcinomas From Renal Lymphomatous Involvement.

Authors:  Carlos Nicolau; Evis Sala; Anita Kumar; Debra A Goldman; Heiko Schoder; Hedvig Hricak; Hebert Alberto Vargas
Journal:  AJR Am J Roentgenol       Date:  2017-01-17       Impact factor: 3.959

4.  Can Initial (18)F-FDG PET-CT Imaging Give Information on Metastasis in Patients with Primary Renal Cell Carcinoma?

Authors:  Haejun Lee; Kyung Hoon Hwang; Seog Gyun Kim; Geon Koh; Ji Hyun Kim
Journal:  Nucl Med Mol Imaging       Date:  2013-11-28

5.  Post-nephrectomy foreign-body granuloma in the retroperitoneum mimicking lymph node metastasis of renal cell cancer.

Authors:  Jindan Luo; Yeqing Mao; Songliang Cai; Xiaoyong Shen; Shanwen Chen; Liping Xie
Journal:  Onco Targets Ther       Date:  2014-11-20       Impact factor: 4.147

6.  Preoperative evaluation of renal cell carcinoma by using 18F-FDG PET/CT.

Authors:  Miwako Takahashi; Haruki Kume; Keitaro Koyama; Tohru Nakagawa; Tetsuya Fujimura; Teppei Morikawa; Masashi Fukayama; Yukio Homma; Kuni Ohtomo; Toshimitsu Momose
Journal:  Clin Nucl Med       Date:  2015-12       Impact factor: 7.794

Review 7.  Role of positron emission tomography/computed tomography in the evaluation of renal cell carcinoma.

Authors:  Rahul Jena; Tushar Aditya Narain; Uday Pratap Singh; Aneesh Srivastava
Journal:  Indian J Urol       Date:  2021-04-01

Review 8.  The Place of FDG PET/CT in Renal Cell Carcinoma: Value and Limitations.

Authors:  Yiyan Liu
Journal:  Front Oncol       Date:  2016-09-06       Impact factor: 6.244

9.  Renal carcinoma CD105-/CD44- cells display stem-like properties in vitro and form aggressive tumors in vivo.

Authors:  M Fiedorowicz; M I Khan; D Strzemecki; J Orzeł; M Wełniak-Kamińska; A Sobiborowicz; M Wieteska; Z Rogulski; L Cheda; W Wargocka-Matuszewska; K Kilian; C Szczylik; A M Czarnecka
Journal:  Sci Rep       Date:  2020-03-25       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.